Home/Pipeline/PRD002

PRD002

HoFH and MASH/MASLD

Discovery/Lead OptimizationActive

Key Facts

Indication
HoFH and MASH/MASLD
Phase
Discovery/Lead Optimization
Status
Active
Company

About PRD Therapeutics

A biotech startup developing the world's first selective SOAT2 inhibitor oral drugs for rare and common lipid metabolism disorders.

View full company profile